Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Immunotherapy has revolutionized cancer treatment. In non-small-cell lung cancer (NSCLC), monotherapy with immune checkpoint inhibitors has improved survival in metastatic disease. Combinations of immune checkpoint inhibitors have shown synergy in preclinical models and are being studied as part of...

Descripción completa

Detalles Bibliográficos
Autores principales: Puri, Sonam, Shafique, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048109/
https://www.ncbi.nlm.nih.gov/pubmed/32158484
http://dx.doi.org/10.7573/dic.2019-9-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048109/
https://www.ncbi.nlm.nih.gov/pubmed/32158484
http://dx.doi.org/10.7573/dic.2019-9-2

Ejemplares similares